drugset

drugset / Trial / NCT00818324

Long Term Administration Study of OPC-12759 Ophthalmic Suspension

NCT00818324 ↗

Phase 3 Completed 154 enrolled Otsuka Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate safety and efficacy of OPC-12759 ophthalmic suspension during 52 weeks in dry eye patients

Timeline

Start: 2009-01
Primary completion: 2010-09
Completion: 2011-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rebamipide	Small molecule	—	Topical

Indications